HMPL-453 in Advanced Malignant Mesothelioma

Inclusion Criteria: * 1.Signed written informed consent; * 2.18 years of age or older; * 3.Histologically diagnosed malignant mesothelioma (including pleura, peritoneum, pericardium, and testicular tendon sheath origin, cell type epithelioid, sarcoma-like, or mixed type), and cannot be cured radically; * 4.Received one to three regimen of prior systemic therapy and then experienced documented radiographic progression or intolerable toxicity; * 5.Patients agreed to provide tumor tissue for FGF/FGFR testing; * 6.Measurable disease by RECIST version 1.1 criteria; * 7.ECOG performance status ≤ 2.; Exclusion Criteria: * 1.Previous treatment with any FGFR inhibitor; * 2.Received systemic anti-cancer therapy within 3 weeks of the first dose of HMPL-453; * 3.Major surgery within 4 weeks of the first dose of HMPL-453; * 4.Use of a strong inducer or inhibitor of cytochrome P450 3A4 (CYP3A4) within 1 week of the first dose of HMPL-453; * 5.Inadequate conditions as indicated by the following laboratory values: * Absolute neutrophil count (ANC)\<1.5 x 109/L * Hemoglobin \< 80 g/L * Platelet count \<80 x 109/L * 6.Any of the following conditions of liver and kidney insufficiency: * Total bilirubin \> 1.5 x ULN * AST and ALT \> 2.5 x ULN (\> 5 x ULN for patients with liver metastases) * Creatinine clearance of \< 50 mL/min as estimated by the Cockcroft-Gault equation * 7.International normalized ratio (INR) \>1.5 or activated partial thromboplastin time (aPTT) \>1.5 x ULN; * 8.Clinical significant liver disease; * 9.Known human immunodeficiency virus (HIV) infection * 10.Previous history of retinal detachment; * 11.Unable to swallow the study drug.